GlaxoSmithKline to Buy Out China Vaccine JV Partner

GlaxoSmithKline is planning totake one of its China vaccine JVs entirely in-house. The company will pay $39 million to Shenzhen Neptunus Interlong Bio-Technique Co. for the 51% of their JV that it does not already own. The JV was established with the goal of supplying seasonal flu, pre-pandemic and pandemic flu vaccines for China, Hong Kong and Macau. More details.... Stock Symbols: (NYSE: GSK) (HKEX: 8329) Share this with colleagues:   var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});